Quest Diagnostics (NYSE: DGX) revenue
Quest Diagnostics reported revenue of $11,035m for fiscal 2025, 11.8% more than in fiscal 2024 ($9,872m). Since fiscal 2016 its revenue has grown by 53.0%, an average growth of 4.8% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $11,035m | +11.8% | $1,556m | 14.1% |
| 2024 | $9,872m | +6.7% | $1,346m | 13.6% |
| 2023 | $9,252m | −6.4% | $1,262m | 13.6% |
| 2022 | $9,883m | −8.4% | $1,428m | 14.4% |
| 2021 | $10,788m | +14.3% | $2,381m | 22.1% |
| 2020 | $9,437m | +22.1% | $1,971m | 20.9% |
| 2019 | $7,726m | +2.6% | $1,231m | 15.9% |
| 2018 | $7,531m | +1.7% | $1,101m | 14.6% |
| 2017 | $7,402m | +2.6% | $1,165m | 15.7% |
| 2016 | $7,214m | — | $1,277m | 17.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Quest Diagnostics
- How much revenue did Quest Diagnostics make in fiscal 2025?
- Quest Diagnostics reported revenue of $11,035m for fiscal 2025, compared with $9,872m in fiscal 2024.
- How much has the revenue of Quest Diagnostics grown?
- Between fiscal 2016 and fiscal 2025 it went from $7,214m to $11,035m: 53.0% more, an average growth of 4.8% a year.
- What was the best year for revenue at Quest Diagnostics?
- Of its last 10 fiscal years, fiscal 2025, with $11,035m.
- Where do the figures for Quest Diagnostics come from?
- From the annual report (Form 10-K) that Quest Diagnostics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Quest Diagnostics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Quest Diagnostics: the Quest Diagnostics page · annual accounts · net income · dividends paid · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.